329 related articles for article (PubMed ID: 10576048)
21. A large, multicentre trial to compare the efficacy and safety of tacrolimus with cyclosporine microemulsion following renal transplantation.
Sperschneider H;
Transplant Proc; 2001; 33(1-2):1279-81. PubMed ID: 11267291
[No Abstract] [Full Text] [Related]
22. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
[TBL] [Abstract][Full Text] [Related]
23. Non-heart-beating donor kidney transplantation under tacrolimus immunosuppression.
Toda F; Tanabe K; Tokumoto T; Ishikawa N; Koga S; Ito S; Yagisawa T; Toma H
Transplant Proc; 2000 Nov; 32(7):1726-9. PubMed ID: 11119909
[No Abstract] [Full Text] [Related]
24. Mycophenolate mofetil with lower cyclosporine dose in high-risk renal transplant recipients.
Esmeraldo RM; Donadi MO; Oliveira ML; Ponte CN; Pinheiro PM
Transplant Proc; 1999 Nov; 31(7):3007-8. PubMed ID: 10578367
[No Abstract] [Full Text] [Related]
25. Conversion to tacrolimus immunosuppression in renal transplant recipients: 12-month follow-up.
Citterio F; Scatà MC; Romagnoli J; Pozzetto U; Nanni G; Castagneto M
Transplant Proc; 2002 Aug; 34(5):1685-6. PubMed ID: 12176535
[No Abstract] [Full Text] [Related]
26. Efficacy and safety of mycophenolate mofetil in different dosages in Asian renal allograft recipients.
Tsang WK; Tong KL; Yeung S; Lee W; Chan HW
Transplant Proc; 2000 Nov; 32(7):1755-6. PubMed ID: 11119921
[No Abstract] [Full Text] [Related]
27. Effect of tacrolimus in renal transplant recipients with immunoglobulin-A nephropathy.
Suzuki K; Tanabe K; Tokumoto T; Shimizu T; Ishikawa N; Yagisawa T; Honda K; Nihei H; Toma H
Transplant Proc; 2000 Nov; 32(7):1730-2. PubMed ID: 11119910
[No Abstract] [Full Text] [Related]
28. Mycofenolate mofetil-cyclosporine immunosuppression of kidney transplantation recipients with two different corticosteroid doses.
Remport A; Sasvári I; Toronyi E; Borka P; Lázár N; Járay J; Perner F
Transplant Proc; 2001 May; 33(3):2302-3. PubMed ID: 11377537
[No Abstract] [Full Text] [Related]
29. Two-year outcome in renal allograft recipients comparing neoral-led with tacrolimus-led therapy.
Wayman MR; Oniscu GC; Forsythe JL; Whitworth CE
Transplant Proc; 2002 Aug; 34(5):1663-5. PubMed ID: 12176526
[No Abstract] [Full Text] [Related]
30. Lipid profile in renal transplant recipients under various immunosuppressive regimens.
Montagnino G; Tarantino A; Aroldi A; Banfi G; Cesana B; Ponticelli C
Transplant Proc; 1994 Oct; 26(5):2634-6. PubMed ID: 7940821
[No Abstract] [Full Text] [Related]
31. Steroid withdrawal in renal transplant recipients.
Oppenheimer F
Transplant Proc; 2000 Feb; 32(1A Suppl):14S-15S. PubMed ID: 10686314
[No Abstract] [Full Text] [Related]
32. Efficacy and safety of tacrolimus versus cyclosporine in kidney and pancreas transplant recipients.
el-Ghoroury M; Hariharan S; Peddi VR; Munda R; Schroeder TJ; Demmy AM; Alexander JW; First MR
Transplant Proc; 1997; 29(1-2):649-51. PubMed ID: 9123461
[No Abstract] [Full Text] [Related]
33. Improved outcome of steroid withdrawal in mycophenolate mofetil-treated primary cadaveric renal transplant recipients.
Kupin W; Venkat KK; Goggins M; Douzdjian V; Escobar F; Mozes M; Abouljoud M
Transplant Proc; 1999; 31(1-2):1131-2. PubMed ID: 10083505
[No Abstract] [Full Text] [Related]
34. Selective CellCept therapy in high-risk renal transplant recipients.
Isenberg A; Singh TP; Shen GK; Freed BM; Conti DJ
Transplant Proc; 1998 Jun; 30(4):1188-9. PubMed ID: 9636480
[No Abstract] [Full Text] [Related]
35. Single center analysis of mycophenolate mofetil and Neoral/prednisone therapy for prophylaxis of rejection in African-American and Caucasian transplant recipients.
Weber M; Ketchum RJ; Sellers M; Aradhye S; Deng S; Grossman R; Shaw L; Naji A; Barker C; Brayman KL
Transplant Proc; 1997; 29(1-2):338-9. PubMed ID: 9123029
[No Abstract] [Full Text] [Related]
36. Postmarketing evaluation of mycophenolate mofetil-based triple therapy immunosuppression compared with a conventional azathioprine-based regimen reveals enhanced efficacy and early pharmacoeconomic benefit after renal transplantation.
Wüthrich RP; Weinreich T; Schwarzkopf AK; Candinas D; Binswanger U
Transplant Proc; 1998 Dec; 30(8):4096-7. PubMed ID: 9865310
[No Abstract] [Full Text] [Related]
37. Trial of steroid withdrawal in renal transplant recipients with long-term--surviving allograft.
Mizuno Y; Kikuchi H; Fujimori K; Doi H; Orii T; Ohkohchi N; Satomi S
Transplant Proc; 2000 Nov; 32(7):1677-8. PubMed ID: 11119888
[No Abstract] [Full Text] [Related]
38. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group.
Jensik SC
Transplant Proc; 1998 Jun; 30(4):1216-8. PubMed ID: 9636494
[No Abstract] [Full Text] [Related]
39. Impact of tacrolimus on hyperlipidemia after renal transplantation: a Japanese single center experience.
Manu M; Tanabe K; Tokumoto T; Ishikawa N; Shimizu T; Okuda H; Ito S; Shimmura H; Inui M; Harano M; Shiroyanagi Y; Yagisawa T; Fuchinoue S; Toma H
Transplant Proc; 2000 Nov; 32(7):1736-8. PubMed ID: 11119912
[No Abstract] [Full Text] [Related]
40. Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. FK506/MMF Dose-Ranging Kidney Transplant Study Group.
Miller J
Transplant Proc; 1999; 31(1-2):276-7. PubMed ID: 10083106
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
